EOLS

Evolus Inc. (EOLS) | Rumor.io

Evolus

EOLS

Attention (50-day avg)0%

Attention rank (50-day avg)#2,970

Bullish sentiment (50-day avg)79%

Price to earnings ratio-9.99

Market capitalization527.7M

Earnings per share-0.53

Dividend yield (TTM)—

Revenue (annual)297.2M

Net income (annual)-51.6M

Social

What share of all stock conversation is about EOLS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

May 5

Evolus, Inc. ($EOLS) reports its second consecutive quarter of positive Adjusted EBITDA, with profitability improvement and a reaffirmed full-year outlook.
The company's cosmetics demand is returning, and it has largely avoided tariff-related effects, according to management, with preparedness measures in place.
Evolus' Q1 results show positive Jeuveau unit growth, but toxin revenue was down YoY, and the company faces mounting pressure on its loss-making, cash-pay aesthetics model due to intensified competition and macro/tariff headwinds.

Generated by AI

Sentiment

Of the messages about EOLS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	0% -87.18	82.07% +3.27
Bearish	—	—	100% +87.18	17.93% -3.27

Bullish· Mar 5

Evolus, Inc. (EOLS) has broken through a key resistance level at $468.77 with a significant volume of 10.54M, indicating a strong bullish momentum.
The company's Q4 earnings have catalyzed a strong rally, with the stock price surging by over 35% to $559.00, driven by a favorable sector rotation and accelerating customer acquisition.
The recent Q4 earnings call has set the stage for a major re-rating, with the company's profit growth accelerating rapidly, signaling a high-conviction momentum play with a potential target of $795.23.

Bearish· Apr 22

$EOLS may have a gap fill eventually, but it could take a long time, potentially even 60 hours.
The stock's price offering of 9 million shares at $9.50 per share has led to a significant decline of -17.9%.
The stock's price has moved below its 50-day Moving Average, indicating a bearish trend, and may test $8 or lower.

Generated by AI

Topics

Of the messages about EOLS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	69.85%
Technical Analysis	—	—	0%	3.52%
Analysts	—	—	0%	4.52%
Macro	—	—	0%	3.02%
Earnings	—	—	0%	19.1%
Controversies	—	—	0%	0%

Earnings· Aug 1

Evolus, Inc. is set to release earnings before the market opens on Thursday.
Analysts expect Evolus to report an earnings per share (EPS) of -0.37.
$EOLS is Evolus, Inc.'s ticker symbol.

Announcements· Mar 4

Evolus, Inc. (EOLS) reported Q4 revenue of $88M-$90M, marking six straight years of double-digit growth, with 2025 revenue expected to reach $296M and 2026 guidance provided.
The company's Q4 earnings call highlighted a strategic partnership to bolster manufacturing and distribution, which contributed to a surge in stock price.
Evolus' Q4 earnings call also revealed a significant expansion of the innovation pipeline, signaling strong future growth potential, and the company secured a major government contract, supporting a strategic pivot.

Technical Analysis· Mar 4

$EOLS has decisively breached the $4.50 resistance level on high volume, confirming a high-momentum breakout with a target of $6.66.
The stock's technical pattern projects a measured move toward $6.66, with the earnings catalyst underpinning the technical thesis.
A major government contract secured in the latest earnings call has been identified as a key catalyst for the stock's breakout, with momentum building and a potential continuation of the move.

Generated by AI

Community

Of the messages about EOLS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	90%	52.49%
Newcomers	—	—	10%	47.51%

Regulars· Jan 17

A large medspa owner is migrating their injections to Jeuveau, Evolus's product, due to better unit economics, potentially impacting Botox sales.
Evolus's Q4 results and 2024 guidance were stronger than expected, with revenue growth and preliminary guidance exceeding consensus estimates.
Evolus's total net revenues for 2023 were approximately $202 million, exceeding guidance and consensus estimates, with a 36% YoY increase.

Newcomers· Mar 5

The stock price of Evolus, Inc. (EOLS) has broken through a key resistance level at $468.77, with a significant volume of 10.54M, and is now targeting $795.23.
The recent Q4 2025 earnings call has been identified as a key catalyst for the stock's surge, with many investors citing the strong momentum and potential for further gains.
The stock's strong technical momentum, combined with the company's recent financial disclosure and favorable sector rotation, has led to a high-risk, high-reward setup, with many investors monitoring the situation closely for potential continuation or reversal.

Generated by AI

On August 5, Evolus (NASDAQ:EOLS) reported second-quarter 2026 results that showed the company finally translating years of growth into the bottom line. Global net revenue reached $84.1 million, up 21% over the prior year, and the company followed that up by raising its full-year 2026 outlook. The quarter also marked the third straight period of […]

22d agoYahoo Finance

Evolus president & CEO David Moatazedi sells $950,018 in shares

26d agoInvesting.com

Wall Street Analysts Think Evolus (EOLS) Could Surge 77.68%: Read This Before Placing a Bet

The mean of analysts' price targets for Evolus (EOLS) points to a 77.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

1mo agoYahoo Finance

Wall Street Analysts Believe Evolus (EOLS) Could Rally 106.08%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 106.1% in Evolus (EOLS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

1mo agoYahoo Finance

Evolus: The Injectable Platform Is Becoming The Real Moat (NASDAQ:EOLS)

1mo agoSeeking Alpha

Evolus signs licensing deal for Profhilo skin injectable in US

1mo agoInvesting.com

Also Discussed

Investors talking about EOLS also mention

#	Name	Attention
1	RVNC - Revance Therapeutics, Inc.	——
2	SkinHealth Systems Inc. Class A Common StockSKIN	0%0
3	Bio-Path Holdings Inc.BPTH	0%0
4	Azul SAAZUL	0%new
5	VCNX - Vaccinex, Inc.	——
6	Edesa Biotech, Inc.EDSA	0%0
7	China Natural Resources, Inc. Common StockCHNR	0%new
8	AEON Biopharma, Inc.AEON	0%new
9	MKDWELL Tech Inc.MKDW	0%+0
10	LanzaTech Global Inc. Common StockLNZA	0%new

Evolus Inc.

Healthcare
Drug Manufacturers - Specialty & Generic

Evolus Inc. is a performance beauty company focused on the cash-pay medical aesthetics market. Evolus Inc. markets Jeuveau, a proprietary neurotoxin used by licensed aesthetic practitioners for temporary improvement in the appearance of moderate to severe frown lines, and Evolysse, a collection of injectable hyaluronic acid gel products for facial aesthetic treatment. The company serves practitioners and consumers across the United States and selected international markets, including Canada, Europe, and Australia, with a business model centered on self-pay aesthetic procedures. Evolus Inc. positions its portfolio around non-reimbursed treatments, combining product commercialization, practitioner support, and brand-led marketing within the medical aesthetics industry.

Website

Location

520 Newport Center Drive

Newport Beach, CA, 92660

United States

Social

What share of all stock conversation is about EOLS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

May 5

Evolus, Inc. ($EOLS) reports its second consecutive quarter of positive Adjusted EBITDA, with profitability improvement and a reaffirmed full-year outlook.
The company's cosmetics demand is returning, and it has largely avoided tariff-related effects, according to management, with preparedness measures in place.
Evolus' Q1 results show positive Jeuveau unit growth, but toxin revenue was down YoY, and the company faces mounting pressure on its loss-making, cash-pay aesthetics model due to intensified competition and macro/tariff headwinds.

Generated by AI

Sentiment

Of the messages about EOLS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	0% -87.18	82.07% +3.27
Bearish	—	—	100% +87.18	17.93% -3.27

Bullish· Mar 5

Evolus, Inc. (EOLS) has broken through a key resistance level at $468.77 with a significant volume of 10.54M, indicating a strong bullish momentum.
The company's Q4 earnings have catalyzed a strong rally, with the stock price surging by over 35% to $559.00, driven by a favorable sector rotation and accelerating customer acquisition.
The recent Q4 earnings call has set the stage for a major re-rating, with the company's profit growth accelerating rapidly, signaling a high-conviction momentum play with a potential target of $795.23.

Bearish· Apr 22

$EOLS may have a gap fill eventually, but it could take a long time, potentially even 60 hours.
The stock's price offering of 9 million shares at $9.50 per share has led to a significant decline of -17.9%.
The stock's price has moved below its 50-day Moving Average, indicating a bearish trend, and may test $8 or lower.

Generated by AI

Topics

Of the messages about EOLS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	69.85%
Technical Analysis	—	—	0%	3.52%
Analysts	—	—	0%	4.52%
Macro	—	—	0%	3.02%
Earnings	—	—	0%	19.1%
Controversies	—	—	0%	0%

Earnings· Aug 1

Evolus, Inc. is set to release earnings before the market opens on Thursday.
Analysts expect Evolus to report an earnings per share (EPS) of -0.37.
$EOLS is Evolus, Inc.'s ticker symbol.

Announcements· Mar 4

Evolus, Inc. (EOLS) reported Q4 revenue of $88M-$90M, marking six straight years of double-digit growth, with 2025 revenue expected to reach $296M and 2026 guidance provided.
The company's Q4 earnings call highlighted a strategic partnership to bolster manufacturing and distribution, which contributed to a surge in stock price.
Evolus' Q4 earnings call also revealed a significant expansion of the innovation pipeline, signaling strong future growth potential, and the company secured a major government contract, supporting a strategic pivot.

Technical Analysis· Mar 4

$EOLS has decisively breached the $4.50 resistance level on high volume, confirming a high-momentum breakout with a target of $6.66.
The stock's technical pattern projects a measured move toward $6.66, with the earnings catalyst underpinning the technical thesis.
A major government contract secured in the latest earnings call has been identified as a key catalyst for the stock's breakout, with momentum building and a potential continuation of the move.

Generated by AI

Community

Of the messages about EOLS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	90%	52.49%
Newcomers	—	—	10%	47.51%

Regulars· Jan 17

A large medspa owner is migrating their injections to Jeuveau, Evolus's product, due to better unit economics, potentially impacting Botox sales.
Evolus's Q4 results and 2024 guidance were stronger than expected, with revenue growth and preliminary guidance exceeding consensus estimates.
Evolus's total net revenues for 2023 were approximately $202 million, exceeding guidance and consensus estimates, with a 36% YoY increase.

Newcomers· Mar 5

The stock price of Evolus, Inc. (EOLS) has broken through a key resistance level at $468.77, with a significant volume of 10.54M, and is now targeting $795.23.
The recent Q4 2025 earnings call has been identified as a key catalyst for the stock's surge, with many investors citing the strong momentum and potential for further gains.
The stock's strong technical momentum, combined with the company's recent financial disclosure and favorable sector rotation, has led to a high-risk, high-reward setup, with many investors monitoring the situation closely for potential continuation or reversal.

Generated by AI

Evolus

Social

May 5

Bullish· Mar 5

Bearish· Apr 22

Earnings· Aug 1

Announcements· Mar 4

Technical Analysis· Mar 4

Regulars· Jan 17

Newcomers· Mar 5

Evolus (EOLS) Notches A Profit Milestone While Betting Big On The Future

Evolus president & CEO David Moatazedi sells $950,018 in shares

Wall Street Analysts Think Evolus (EOLS) Could Surge 77.68%: Read This Before Placing a Bet

Wall Street Analysts Believe Evolus (EOLS) Could Rally 106.08%: Here's is How to Trade

Evolus: The Injectable Platform Is Becoming The Real Moat (NASDAQ:EOLS)

Evolus signs licensing deal for Profhilo skin injectable in US

Also Discussed

Evolus Inc.

Company Information

Location

Evolus (EOLS) Notches A Profit Milestone While Betting Big On The Future

Evolus president & CEO David Moatazedi sells $950,018 in shares

Wall Street Analysts Think Evolus (EOLS) Could Surge 77.68%: Read This Before Placing a Bet

Wall Street Analysts Believe Evolus (EOLS) Could Rally 106.08%: Here's is How to Trade

Evolus: The Injectable Platform Is Becoming The Real Moat (NASDAQ:EOLS)

Evolus signs licensing deal for Profhilo skin injectable in US

Also Discussed

Social

May 5

Bullish· Mar 5

Bearish· Apr 22

Earnings· Aug 1

Announcements· Mar 4

Technical Analysis· Mar 4

Regulars· Jan 17

Newcomers· Mar 5